WaveMan
WaveMan · Company
NAGE · Niagen Bioscience, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NAGE Niagen Bioscience (NAGE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001386570
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
65
13F, latest reported quarter

Niagen Bioscience insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Niagen Bioscience, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Pamir Ozan
Chief Financial Officer
BUY
2025-11-17 SECtraded 2025-11-14
4,464.96
$30.4K
-64.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 60.6% of the 7,372 shares held after it.
  • No other insider bought within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Pamir Ozan bought about $30.4K of NAGE on Nov 14, 2025, the largest insider purchase at the company on our record; 65 funds added in the latest 13F quarter.
Pamir Ozan
Chief Financial Officer
BUY
2025-11-17 SECtraded 2025-11-14
2,220.44
$15.2K
-64.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 2,220 shares held after it.
  • No other insider bought within 30 days.
  • 65 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Pamir Ozan bought about $15.2K of NAGE on Nov 14, 2025, the largest insider purchase at the company on our record; 65 funds added in the latest 13F quarter.
2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
65 funds bought in last quarter
more than 54% of Pharma & Biotech
Revenue
+29.9% year over year
more than 71% of Pharma & Biotech
Margin
13.4% net margin
more than 83% of Pharma & Biotech
Buybacks
$5.1M repurchased, FY to 2026-06-30
below 79% of Pharma & Biotech
Short interest
7.1% of the float short (float per yahoo 2026-10-27) · 6.2 days to cover · settled 2026-10-15
more than 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NAGE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-67.1%12M
-67%-44%-21%+2%2025-102025-122026-022026-042026-062026-082026-10 2025-11-14 · Pamir Ozan bought $30.4K2025-11-14 · Pamir Ozan bought $15.2K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NAGE: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,184,659 sh
$13.3M
SteelPeak Wealth, LLC
3,500,129 sh
$11.2M
VANGUARD CAPITAL MANAGEMENT LLC
2,147,018 sh
$6.8M
Qube Research & Technologies Ltd
1,625,016 sh
$5.2M
GEODE CAPITAL MANAGEMENT, LLC
1,478,603 sh
$4.7M

Congress trades in NAGE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NAGE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NAGE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Gabelli Love Our Planet & People ETF
$67.0K position · as of 2026-06-30
0.4%
Invesco NASDAQ Future Gen 200 ETF
$58.7K position · as of 2026-05-31
0.3%
ACUITAS US MICROCAP FUND
$321.4K position · as of 2026-06-30
0.3%
Gabelli Global Mini Mites Fund
$73.4K position · as of 2026-06-30
0.3%
Amplify Etho Climate Leadership U.S. ETF
$394.0K position · as of 2026-06-30
0.2%
Columbia Integrated Small Cap Growth Fund
$65.4K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Robert Fried
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.4M
$10.3M
$637.2K
+32%
+48%
2024
$1.2M
$3.0M
$408.7K
+11%
+17%
2023
$1.2M
$1.0M
$691.6K
-70%
+13%
2022
$1.2M
$843.4K
$721.4K
-65%
+13%
2021
$1.1M
$2.1M
$786.3K
-22%
+11%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 65 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NAGE financials

Revenue growth
+29.9%
XBRL, annual
Net margin
13.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$129.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+12.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$5.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+21.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+16.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
no debt line filed
Return on capital employed
+13.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
13.56x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
+2.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing EPS growth -14%, PEG needs growth
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$129.4M$99.6M$83.6M$72.0M
Gross profit$83.2M$61.6M$50.8M$42.8M
Operating income$16.3M$7.7M-$5.6M-$18.6M
Net income$17.4M$8.6M-$4.9M-$16.5M
EPS (diluted)0.200.11-0.07-0.24
Operating cash flow$13.5M$12.1M$7.1M-$15.1M
Cashn/a$44.5M$27.2M$20.3M
Buybacks$251.0K$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

NAGE Stock Sonar score 4/7 axes

Find similar shapesCompare

NAGE ranks highest on profitability (91st percentile) and growth (71st), and lowest on risk and compliance (46th), among Pharma & Biotech peers.

Profitability
91
Inputs
  • Return on equity+21.8% · 89 pct, sector of 545
  • Return on assets+16.1% · 91 pct, sector of 691
  • Return on invested capitalno debt line filed
  • Return on capital employed+13.2% · 92 pct, sector of 576
Growth
71
Inputs
  • Revenue growth, YoY+29.9% · 71 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
54
Inputs
  • Funds adding, latest quarter65 · 54 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
46
Inputs
  • Short interest, % of float+7.1% · 50 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.4% · 41 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies